The proteasome inhibitor
carfilzomib has taken on an increasing role in the treatment of multiple myeloma
s proteasome inhibitor
, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma, Triphase said.
Bortezomib, a proteasome inhibitor
, and dexamethasone, a corticosteroid, are both common therapies used to treat symptomatic multiple myeloma.
Ixazomib, a proteasome inhibitor
, is also given in combination with lenalidomide and dexamethasone, so the concerns are the same.
Iceni Pharmaceuticals is planning a Phase II safety/efficacy trial of Cilcane starting in 2017 aimed at relapsed refractory patients who have already received one prior therapy of proteasome inhibitor
Bortezomib, the first therapeutic proteasome inhibitor
, is one of the primary agents in the treatment of multiple myeloma (MM).
The major medications used for chemotherapy include various combinations of the following agents: the immunomodulators thalidomide and lenalidomide; the proteasome inhibitor
bortezomib; the alkylating agents melphalan and cyclophosphamide; and the steroids dexamethasone and prednisone.
A furan-structure has been shown to be involved in some 20S proteasome inhibitor
, we next designed this study to investigate if terazosin is able to inhibit proteasome activity and if proteasome activity inhibition is one of molecule mechanisms mediate anti-cancer cell activity of terazosin.
Bortezomib is a reversible proteasome inhibitor
, currently approved by US FDA for use in multiple myeloma and mantle cell lymphoma.
The multi-center study with MLN9708, an investigational, oral proteasome inhibitor
, will be conducted in Europe and North America.
In July 2012, the market reached a new milestone with the approval of Onyx's Kyprolis, a proteasome inhibitor
with an improved safety profile and potential to be another blockbuster.
Phase 1 trial of the proteasome inhibitor
PS-341 in patients with refractory hematologic malignancies.